About ImmuDyne (OTCMKTS:IMMD)
Immudyne, Inc. manufactures, distributes, and sells natural immune support products primarily in the United States. It operates in two segments, Nutraceutical and Cosmetic Additives, and Finished Cosmetic Products. The company offers nutraceutical and cosmetic product lines, including yeast beta glucans that are natural extracts for various oral and topical applications. Its nutraceutical and cosmetic products for yeast beta glucans are oral daily supplements, such as dietary supplements to support immune system function; and topical lines of rejuvenating serums and creams that are intended to support the skin's immune system response and defense, skin renewal, and to repair sun and environmental damage. Immudyne, Inc. sells its products directly and through distributors to pharmaceutical, nutraceutical, and consumer product companies, as well as consumers. The company was formerly known as Anina Resources, Inc. Immudyne, Inc. was incorporated in 1987 and is based in Mount Kisco, New York.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:IMMD
CUSIPN/A
Phone866-351-5907
Debt
Debt-to-Equity RatioN/A
Current Ratio1.97%
Quick Ratio0.88%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.05 million
Price / Sales2.68
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book32.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-1,200,000.00
Net Margins-23.82%
Return on EquityN/A
Return on Assets-97.05%
Miscellaneous
Employees10
Outstanding Shares42,260,000
ImmuDyne (OTCMKTS:IMMD) Frequently Asked Questions
What is ImmuDyne's stock symbol?
ImmuDyne trades on the OTCMKTS under the ticker symbol "IMMD."
Who are some of ImmuDyne's key competitors?
Some companies that are related to ImmuDyne include Kitov Pharma (KTOV), Neuralstem (CUR), Interpace Diagnostics Gr (IDXG), AIT Therapeutics (AITB), Tonix Pharmaceuticals (TNXP), Regenerx Biopharmaceuticals (RGRX), Akari Therapeutics (AKTX), DelMar Pharmaceuticals (DMPI), Akers Biosciences (AKR), ContraVir Pharmaceuticals (CTRV), AEterna Zentaris (AEZS), Dynatronics (DYNT), Neovasc (NVCN), IntelliPharmaCeutics Intl (IPCI), Oncobiologics (ONS), AmpliPhi Biosciences (APHB), EnteroMedics (RSLS) and Cellectar Biosciences (CLRB).
Who are ImmuDyne's key executives?
ImmuDyne's management team includes the folowing people:
- Mr. Justin Schreiber, CEO, Pres & Director (Age 35)
- Mr. Stefan Galluppi, COO, CTO & Chief Exec. Officer of Immudyne PR (Age 31)
- Dr. Joseph V. DiTrolio M.D., Chief Medical Officer of North America & Director (Age 67)
- Dr. Sven M. Rohmann M.D., Ph.D., MBA, Chairman of Medical Advisory Board & Chief Medical Officer (Age 56)
- Mr. Robert Kalkstein, Chief Financial Officer (Age 36)
Has ImmuDyne been receiving favorable news coverage?
News articles about IMMD stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ImmuDyne earned a media sentiment score of 0.13 on Accern's scale. They also gave press coverage about the company an impact score of 45.32 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of ImmuDyne?
Shares of IMMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmuDyne's stock price today?
One share of IMMD stock can currently be purchased for approximately $0.32.
How big of a company is ImmuDyne?
ImmuDyne has a market capitalization of $13.52 million and generates $5.05 million in revenue each year. ImmuDyne employs 10 workers across the globe.
How can I contact ImmuDyne?
ImmuDyne's mailing address is 1460 BROADWAY, NEW YORK NY, 10036. The company can be reached via phone at 866-351-5907.
MarketBeat Community Rating for ImmuDyne (IMMD)
MarketBeat's community ratings are surveys of what our community members think about ImmuDyne and other stocks. Vote "Outperform" if you believe IMMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
ImmuDyne (OTCMKTS:IMMD) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 4/19/2016 forward)
ImmuDyne (OTCMKTS:IMMD) Earnings History and Estimates Chart
ImmuDyne (OTCMKTS IMMD) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/14/2017 | Q3 2017 | | ($0.02) | | $2.05 million | View | N/A |  |
| 8/14/2017 | Q2 2017 | | $0.02 | | $1.11 million | View | N/A | |
| 7/7/2017 | Q1 2017 | | ($0.03) | | $0.42 million | View | N/A | |
| 11/15/2016 | Q3 2016 | | ($0.01) | | $1.38 million | View | N/A | |
| 8/15/2016 | Q2 2016 | | ($0.01) | | $1.23 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
ImmuDyne (OTCMKTS:IMMD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ImmuDyne (OTCMKTS IMMD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | ImmuDyne Inc (IMMD) CEO Buys $55,250.00 in Stock
www.americanbankingnews.com - March 28 at 10:48 PM |
 | ImmuDyne Signs Exclusive License Agreement for Clinically-Backed Solar Purpura Product
finance.yahoo.com - March 28 at 10:22 AM |
| Immudyne Announces Launch of INR Wellness Immune Support Product Line
finance.yahoo.com - March 19 at 10:20 AM |
| ImmuDyne Inc (IMMD) Insider Purchases $138,000.00 in Stock
www.americanbankingnews.com - February 12 at 6:46 PM |
| ImmuDyne Announces Management Changes & Sale of Legacy Manufacturing Business
finance.yahoo.com - January 30 at 8:56 AM |
| ImmuDyne Announces Appointment of Amilya Antonetti as Chief Digital Strategist
finance.yahoo.com - December 13 at 8:46 AM |
 | ImmuDyne Announces Strategic Blockchain-Linked Investment - GlobeNewswire (press release)
globenewswire.com - November 29 at 8:29 AM |
| Immudyne, Inc. :IMMD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 8:29 AM |
| ImmuDyne Announces Strategic Blockchain-Linked Investment
finance.yahoo.com - November 27 at 5:23 PM |
| Immudyne, Inc. :IMMD-US: Earnings Analysis: Q4, 2016 By the Numbers : May 29, 2017
finance.yahoo.com - November 3 at 1:50 PM |
| Immudyne, Inc. :IMMD-US: Earnings Analysis: Q1, 2017 By the Numbers : July 10, 2017
finance.yahoo.com - November 3 at 1:50 PM |
| Immudyne, Inc. :IMMD-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - November 3 at 1:50 PM |
| ImmuDyne Forecasts Record Third Quarter 2017 Revenue
finance.yahoo.com - November 3 at 1:50 PM |
| ImmuDyne Announces New CFO to Take Company through Next Phase of Growth
finance.yahoo.com - November 3 at 1:50 PM |
| ImmuDyne Announces Record Third Quarter 2017 Revenue
finance.yahoo.com - November 3 at 1:50 PM |
ImmuDyne (OTCMKTS:IMMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
ImmuDyne (OTCMKTS IMMD) Stock Chart for Thursday, April, 19, 2018
Loading chart…
